Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
Journal of Clinical Medicine
|
October 23, 2021
Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis
Alessio Martucci, Doriana Landi, Massimo Cesareo, et al.
Molecular Neurobiology
|
April 3, 2024
Post-COVID-19 Hyposmia Does Not Exhibit Main Neurodegeneration Markers in the Olfactory Pathway
Tommaso Schirinzi, Daniela Maftei, Riccardo Maurizi, et al.
European Journal of Neurology
|
September 13, 2022
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study
Fabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, et al.
Journal of Neurology
|
July 19, 2023
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study
Fabrizio Vernieri, Nicoletta Brunelli, Simona Guerzoni, et al.
The Journal of Headache and Pain
|
November 1, 2022
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
April 15, 2021
Narrative Medicine to integrate patients', caregivers' and clinicians' migraine experiences: the DRONE multicentre project
Maria Clara Tonini, Alessandra Fiorencis, Rosario Iannacchero, et al.
The Journal of Headache and Pain
|
May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
Journal of Neurology
|
June 28, 2022
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience
Claudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
European Journal of Neurology
|
November 26, 2021
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study
Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
The Journal of Headache and Pain
|
April 29, 2021
Medication overuse and drug addiction: a narrative review from addiction perspective
Tatiane Teru Takahashi, Raffaele Ornello, Giuseppe Quatrosi, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
Journal of Clinical Medicine
|
October 23, 2021
Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis
Alessio Martucci, Doriana Landi, Massimo Cesareo, et al.
Molecular Neurobiology
|
April 3, 2024
Post-COVID-19 Hyposmia Does Not Exhibit Main Neurodegeneration Markers in the Olfactory Pathway
Tommaso Schirinzi, Daniela Maftei, Riccardo Maurizi, et al.
European Journal of Neurology
|
September 13, 2022
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study
Fabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, et al.
Journal of Neurology
|
July 19, 2023
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study
Fabrizio Vernieri, Nicoletta Brunelli, Simona Guerzoni, et al.
The Journal of Headache and Pain
|
November 1, 2022
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
April 15, 2021
Narrative Medicine to integrate patients', caregivers' and clinicians' migraine experiences: the DRONE multicentre project
Maria Clara Tonini, Alessandra Fiorencis, Rosario Iannacchero, et al.
The Journal of Headache and Pain
|
May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
Journal of Neurology
|
June 28, 2022
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience
Claudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
European Journal of Neurology
|
November 26, 2021
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study
Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
The Journal of Headache and Pain
|
April 29, 2021
Medication overuse and drug addiction: a narrative review from addiction perspective
Tatiane Teru Takahashi, Raffaele Ornello, Giuseppe Quatrosi, et al.
Page
of 9